Chronic natural killer-cell lymphocytosis successfully treated with alemtuzumab.
Chee
Cheng E
CE
Warrington
Kenneth J
KJ
Tefferi
Ayalew
A
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D006801:Humans; D007694:Killer Cells, Natural; D054068:Livedo Reticularis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D008218:Lymphocytosis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010488:Polyarteritis Nodosa / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab